Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer

Bruno Bockorny, MD, a an attending physician for medical oncology/hematology at Beth Israel Deaconess Medical Center, an assistant professor of medicine at Harvard Medical School, and researcher of Cellular Biology at Beth Israel Deaconess Medical Center, discusses the findings from a study of botensilimab (AGEN1181) plus bastilimab (AGEN2034) for the treatment of patients with recurrent platinum refractory/resistant ovarian cancer (NCT03860272).

Results from the phase 1/2 study were presented by Bockorny, the principal investigator, during The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer. Results suggested that the clinical benefit of botensilimab plus bastiliimab was superior to that of standard-of-care therapy.

TRANSCRIPT:

0:08 | So, in this population of our patients with ovarian cancer we will present data on all 24 patients. What's key here is that this patient population has been heavily pretreated. They had a median of 4 prior lines of therapy. About 20% of them had actually previously received immunotherapy. And in this heavily pretreated population, we observed objective response rate of 33%. There were another 33% of patients who had stable disease, the late adding up to 67% of patients who had disease control. These numbers are substantially higher than what we would expect for a traditional combination of immunotherapy. Traditionally, the response rate to immunotherapy in patients with ovarian cancer it's been between 3% and 10%.

1:15 | Key highlights were the objective response rates that we are seeing these heavily pretreated population is significantly higher than what we would expect for traditional immunotherapy combination. We are also seeing that the safety profile has been comparable to what we would expect for traditional immunotherapy. I think what's also unique with this combination is that we are seeing very little high-grade visceral toxicity outside the GI tract. That's unique for this combination and good for our patients. The trial is ongoing, so we continue to enroll patients with ovarian cancer. Also relevant for SGO, we ar enrolling patients with endometrial cancer.